~~<i id='775F3EBB04'><strike id='775F3EBB04'><tt id='775F3EBB04'><pre id='775F3EBB04'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

comprehensive

author：Wikipedia 2025-10-01 06:01:48 - browse：486

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Why Titanic fascinates society, still drawing tours to the wreckage

leisure time

entertainment

hotspot

entertainment

focus

1:10PresidentJoeBidenparticipatesinaceremonialarrivalandinspectionofthehonorguardwithBritain'sKingCh

WSS

Drinking water from half of US faucets contains PFAS: Study

Tennessee woman gets emergency hysterectomy after doctors deny early abortion care

How corporate America is slashing DEI workers amid backlash to diversity programs

Tennessee woman gets emergency hysterectomy after doctors deny early abortion care

Masked men burn a market in a Mexican city plagued by gang violence, killing 9 people

Why you get paid to donate plasma but not blood

focus

comprehensive

leisure time

Sports medicine is finally prioritizing gender equality

A Theranos scientist

What does generative AI mean for health care? We asked experts

More hospitals are billing patients as online messages surge

After affirmative action ruling, medical educators look to 'holistic review'

Kansas must stop changing trans people's sex listing on driver's licenses, judge says

Moonlake's readout produced a cash windfall. Risks remain

What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

Hollywood unions extend contract negotiations for actors

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

leisure time

Ahead of NATO summit, Biden meets with King Charles for 1st time since coronation

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

UPS workers' union leader explains what's at stake as strike edges closer

FDA approves Leqembi, a milestone in Alzheimer’s treatment

Rare Northern Lights show in US this week: Where and how to see it

Johnson & Johnson sues to stop Medicare negotiation

entertainment

hotspot

entertainment

focus